Can All Ovarian Cancer Patients Get Recommended Chemotherapy?
Author Information
Author(s): McNally O M, Delaney E, Petty R D, Cruickshank M E, Hutcheon A W, Parkin D E
Primary Institution: Aberdeen Royal Infirmary
Hypothesis
Is NICE guidance on chemotherapy for ovarian cancer implementable in our population?
Conclusion
The study found that combination treatment based on NICE guidance is not deliverable in all patients with ovarian cancer.
Supporting Evidence
- 85% of patients had surgical staging.
- 29% of patients received chemotherapy within a clinical trial.
- 94% of patients indicated for treatment received some form of adjuvant treatment.
Takeaway
The study looked at whether all patients with ovarian cancer could get the recommended chemotherapy, and it found that not everyone could.
Methodology
A prospective population-based study was conducted on patients with newly diagnosed epithelial ovarian cancer from a cancer database.
Potential Biases
Potential bias due to the centralized referral system and funding availability.
Limitations
The study may not represent all regions due to differences in healthcare delivery systems.
Participant Demographics
Median age of participants was 58 years, with a range from 30 to 83 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website